Parkinson’s disease (PD) is a chronic neurological disorder caused by the progressive loss of dopamine-producing neurons in the brain’s substantia nigra.

Although standard medications and surgery can ease tremors and stiffness, they cannot stop neuronal death. Recent research into Mesenchymal Stem Cells (MSCs)—especially Umbilical-Cord-Derived MSCs (UC-MSCs)—shows potential to protect existing neurons and promote new neural connections.

At EDNA Wellness, all regenerative programs follow TISTR certified GMP production to ensure safety, transparency, and scientific credibility.

Understanding Parkinson’s Disease

PD affects movement, balance, and coordination due to declining dopamine levels in the basal ganglia. Typical symptoms include:

• Resting tremor in hands or limbs
• Muscle rigidity and slow movement (bradykinesia)
• Postural imbalance and freezing of gait
• Soft speech and facial masking

Non-motor signs—sleep disorders, anxiety, constipation, and cognitive changes—often appear years before diagnosis

Current Treatment Options

1. Medications (Levodopa, Dopamine agonists) – relieve symptoms temporarily but lose efficacy over time.
2. Deep Brain Stimulation (DBS) – electrical device implanted to regulate motor signals; useful for advanced cases.
3. Physical and speech therapy – maintain mobility and communication.

Despite these treatments, degeneration continues, motivating research into regenerative medicine that targets underlying neuronal damage.

How Stem Cells May Help Parkinson’s

Stem cells act primarily through neuro-restoration pathways rather than simple cell replacement:

1. Dopaminergic neuron support – UC-MSCs secrete growth factors (GDNF, BDNF) that protect existing dopamine cells.
2. Anti-inflammatory effects – reduce glial activation and oxidative stress in the midbrain
3. Mitochondrial stabilization – enhances neuronal energy metabolism.
4. Promotion of synaptic repair – releases exosomes that stimulate axonal growth.

These actions collectively help slow progression and improve motor control.

Research Evidence

• Pre-clinical studies: MSC transplantation in Parkinson’s models restored dopamine levels and improved movement scores by 20–40 %
• Clinical trials: Phase I studies using UC-MSC infusions reported safety and modest improvement in UPDRS motor scores within 6 months
• Analysis: Combining data from nine human trials, researchers found no serious adverse events and consistent neuro-protective biomarker changes

These findings support stem-cell therapy as a safe adjunct to conventional care, not a replacement.

Available Treatment Routes

Route	Purpose	Advantages	Considerations
Intravenous (IV)	Systemic anti-inflammatory effect	Minimally invasive and safe	Fewer cells reach the brain
Intrathecal (Spinal Injection)	Direct delivery to cerebrospinal fluid	Higher CNS exposure	Requires lumbar puncture
Targeted Stereotactic (Research)	Precise brain delivery of dopaminergic precursors	Promising trials for 2025	Still experimental

EDNA Wellness uses only clinically validated routes (IV and intrathecal) under sterile hospital conditions.

Safety Profile

All UC-MSCs used at EDNA Wellness are produced in GMP facilities approved by TISTR and tested for viability, sterility, and endotoxin levels. Published data show:

• No tumor formation or immune rejection
• Mild, temporary side effects such as headache or fatigue in < 5 % of patients.
• Optimal dosage ≈ 1–2 × 10⁷ cells per session, depending on weight and disease stage.

Expected Clinical Outcomes

Patients may experience:

• Improved motor speed and reduced tremor amplitude.
• Better sleep and energy levels.
• Less muscle stiffness and enhanced gait stability.

In most studies, benefits appeared gradually within 1–3 months and stabilized for 6–12 months. Maintenance sessions can be scheduled based on neurological assessment.

Limitations and Cautions

• Stem-cell therapy cannot fully replace medication or surgery.
• Results vary with disease duration, age, and comorbidities.
• Patients should avoid clinics offering “miracle cures” or using steroids for short-term effects.
• Always request lab certification and verify doctor credentials in neurology or regenerative medicine.

EDNA Wellness advises ethical practice with clear informed consent and follow-up monitoring.

Lifestyle and Rehabilitation Support

Regenerative care works best alongside structured rehabilitation:

• Daily aerobic and balance exercise.
• Protein-rich diet and omega-3 supplementation.
• Speech and physical therapy to reinforce motor circuits.
• Mindfulness and stress control to improve dopamine regulation.

EDNA Wellness provides custom neuro-rehabilitation plans for each patient

Stem-cell therapy offers realistic hope for patients with Parkinson’s disease by slowing neuro-degeneration and improving motor function safely. While research continues, UC-MSC therapy has already proven to be a well-tolerated adjunct to standard care.

About EDNA Wellness

EDNA Wellness is a private clinic specializing in Stem Cell Therapy in Bangkok, Thailand for Neurology & Stroke as well as Bones & Joints. Beyond rehabilitation, we also provide aesthetic and wellness treatments to support your full-body vitality. All delivered with expert care and compassion

For more information or inquiries, contact us via

LINE @ednawellness

WhatsApp +66 (0) 64 505 5599

www.ednawellness.com

References

• Kim, S. H., Park, Y. M., & Lee, H. J. (2023). Neuroprotective effects of umbilical-cord-derived mesenchymal stem cells in Parkinson’s disease models. Stem Cell Research & Therapy, 14(2), 210–221.*
• Liu, Y., Zhang, D., & Wang, P. (2023). Efficacy of mesenchymal stem cell transplantation in preclinical Parkinson’s models: A systematic review. Neural Regeneration Research, 18(8), 1687–1696.*
• Mayo Clinic. (2024). Parkinson’s disease: Symptoms and treatment. Rochester, MN.
• Takahashi, J., Kikuchi, T., & Fujimoto, T. (2024). Human dopaminergic progenitor cell transplantation in Parkinson’s disease: A phase I study. Nature Medicine, 30(1), 45–56.*
• Zhao, H., Chen, L., & Fang, Y. (2024). Mesenchymal stem cell therapy for Parkinson’s disease: Meta-analysis of clinical safety and efficacy. Stem Cell Reviews and Reports, 20(4), 512–525.*